Trial · NCT04209595
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase I - Maximum Tolerated Dose | STARTED | Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg | 0 | |
| Phase I - Maximum Tolerated Dose | STARTED | Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg | 8 | |
| Phase I - Maximum Tolerated Dose | STARTED | Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg | 2 | |
| Phase I - Maximum Tolerated Dose | STARTED | Phase IIA Arm 2 | 0 | |
| Phase I - Maximum Tolerated Dose | STARTED | Phase IIB Arm 2 | 0 | |
| Phase I - Maximum Tolerated Dose | COMPLETED | Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg | 0 | |
| Phase I - Maximum Tolerated Dose | COMPLETED | Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg | 8 | |
| Phase I - Maximum Tolerated Dose | COMPLETED | Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg | 2 | |
| Phase I - Maximum Tolerated Dose | COMPLETED | Phase IIA Arm 2 | 0 | |
| Phase I - Maximum Tolerated Dose | COMPLETED | Phase IIB Arm 2 | 0 | |
| Phase I - Maximum Tolerated Dose | NOT COMPLETED | Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg | 0 | |
| Phase I - Maximum Tolerated Dose | NOT COMPLETED | Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg | 0 | |
| Phase I - Maximum Tolerated Dose | NOT COMPLETED | Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg | 0 | |
| Phase I - Maximum Tolerated Dose | NOT COMPLETED | Phase IIA Arm 2 | 0 | |
| Phase I - Maximum Tolerated Dose | NOT COMPLETED | Phase IIB Arm 2 | 0 | |
| Phase IIA - Assess Efficacy | STARTED | Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg | 0 | |
| Phase IIA - Assess Efficacy | STARTED | Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg | 0 | |
| Phase IIA - Assess Efficacy | STARTED | Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg | 0 | |
| Phase IIA - Assess Efficacy | STARTED | Phase IIA Arm 2 | 0 | |
| Phase IIA - Assess Efficacy | STARTED | Phase IIB Arm 2 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04209595/flow